

1 **Comparative analysis unveils novel changes in serum
2 metabolites and metabolomic networks of retinopathy of
3 prematurity infants**

4

5

6 **Yuhang Yang¹, Qian Yang², Yinsheng Zhang³, Chaohui Lian⁴, Honghui He¹,
7 Jian Zeng¹, Guoming Zhang*¹**

8

9

10

11 1 Shenzhen eye hospital, Shenzhen key ophthalmic laboratory, the second affiliated
12 hospital of Jinan university, 18 Zetian Road, Shenzhen, Guangdong, 518040, China

13 2 UCL Institute of Ophthalmology, University College London, 11-43 Bath Street,
14 London EC1V 9EL, United Kingdom.

15 3 School of Management and E-Business, Zhejiang Gongshang University, Hangzhou
16 310018, China

17 4 Shenzhen Maternal and Child Health Hospital, Shenzhen key prevention and control
18 laboratory of birth defect, the affiliated hospital of Southern Medical University, 2004
19 Hongli Road, Shenzhen, Guangdong, 518017, China

20

21

22 **Correspondence:** Zhang Guoming, MD, PhD, Shenzhen Eye Hospital, Shenzhen key
23 ophthalmic laboratory, the second affiliated hospital of Jinan university, 15 Zetian
24 Road, Shenzhen, Guangdong, 518040, China; zhang-guoming@163.com

25

26

27 **Sources of funding:** The research was supported by Shenzhen Science and
28 Technology Innovation Commission basic discipline layout project, China
29 (JCYJ20170817112542555) and Medical and health projects of Sanming.

30

31 **Conflict of interest statement:** The authors have declared that no conflict of interest
32 exists.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

33 **Abstract**

34 **Background:** Advances in mass spectrometry are providing new insights into
35 the role of metabolomics in the aetiology of many diseases. Studies in retinopathy of
36 prematurity (ROP), for instance, overlooked the role of metabolic alterations in
37 disease development. Here, we employed comprehensive metabolic profiling and
38 gold-standard metabolic analysis to explore major metabolites and metabolic
39 pathways significantly affected in early stages of pathogenesis toward ROP.

40 **Methods:** This is a multicentre, retrospective case-control study. We collected
41 serums from 57 ROP cases and 57 strictly baseline matched non-ROP controls.
42 Non-targeted ultrahigh performance liquid chromatography-tandem mass
43 spectroscopy (UPLC-MS/MS) from Metabolon, Inc. was used to detect the
44 metabolites in serum samples. Machine learning was used to unravel most affected
45 metabolites and pathways in ROP development.

46 **Results:** Compared to non-ROP controls, we found a significant metabolic
47 perturbation in the ROP serums, featured with an increase in lipid, nucleotide,
48 carbohydrate metabolites and a lower level of peptides. Machine learning helped to
49 distinguish a cluster of metabolic pathways (glycometabolism, redox homeostasis,
50 lipid metabolism and arginine pathway) that were strongly related to the development
51 of ROP. In addition, we found that the severity of ROP was related to the level of
52 creatinine and ribitol.

53 **Conclusion:** In the current study, our results suggested a strong link between
54 metabolic profiling and retinal neovascularization during ROP pathogenesis. These
55 findings provided an insight into identifying novel metabolic biomarkers for ROP
56 diagnosis and prevention.

57 **Keywords:** retinopathy of prematurity, metabolomics, metabolites, biomarkers,
58 mechanisms of disease

59

60 **Introduction**

61 Retinopathy of prematurity (ROP) is characterized by the presence of retinal
62 ischemia and retinal neovascularization which may lead to a retinal detachment which
63 was first reported by Terry since the forties of the last century. It is a potential blind
64 retinopathy disease that occurs commonly in preterm or preterm very low birth weight
65 (VLBW) infants^[22, 26]. Despite of improvement of neonatal intensive care and
66 increased survival rates of VLBW infants in low- and middle-income countries^[4, 19],
67 the incidence and severity of ROP maintained at a high level^[10, 46]. A recent
68 epidemiological study reported that, worldwide, approximately 100,000 children
69 suffering from blindness are due to ROP^[26, 31].

70 There are some limitations of current screening and treatment strategies of ROP.
71 Clinically diagnosis of ROP relies on indirect ophthalmoscopy and colour fundus
72 images following the International Classification of ROP (ICROP)^[37], yet these two
73 methods merely provide information about pathological change in the eye. Current
74 therapeutic approaches to ROP include retinal laser photocoagulation and intravitreal
75 injection of anti-vascular endothelial growth factor (VEGF) agents. However, risks
76 have been identified on damaging the iris, lens and choroidal rupture by laser
77 photocoagulation, which may also lead to constricted visual field and refractive errors
78 in the future^[52]. Injection of anti-VEGF agent to premature infants has raised concerns
79 about infection, suppression on systemic normal vascular development and even
80 inhibiting the growth of central nervous system^[21, 43]. Furthermore, current treatments
81 only aim at those who have already developed ROP, at which stage the damage in the
82 eye is irreversible. Therefore, it would of urgent and great need to develop a
83 preventative tactic to identify high-risk groups at an earlier stage and prevent disease
84 progression effectively.

85 Metabolomics aims at the holistic measurement of a considerable number of
86 small molecules (metabolites) from a biological sample. It is a rapidly evolving field
87 in biochemical research and is regarded as a complementary technology to other

88 “omics” techniques^[50]. To the best of our knowledge, this is the first study performing
89 metabolomic analysis on serums from ROP and control infants and comprehensively
90 compare alteration in the metabolic profiles between groups; we aim to provide an
91 insight into early diagnosis and treatment by identifying specific biomarkers and
92 relevant pathways.

93 **Methods**

94 **2.1. Study Design**

95 This is a multicentre case-control study with data collected between April 2018
96 and October 2019 from neonatal intensive care units (NICU) of 22 hospitals in
97 Shenzhen, China. This study, adhered to the tenets of the Declaration of Helsinki, has
98 been reviewed and approved by the medical ethics committee of all hospitals and has
99 been registered at ClinicalTrials.gov (ChiCTR1900020677). Signed enrolment
100 consent forms were obtained from all families. Infants were enrolled if they were born
101 preterm (between 20 weeks to 37 weeks from gestation). A total of 114 patients
102 fulfilled the inclusion criteria. The presence of ROP was determined by specialized
103 ophthalmologists from Shenzhen Eye Hospital. The classification criteria were as
104 follows: (1) ROP group: Severe ROP that required treatment (aggressive posterior
105 retinopathy of prematurity (AP-ROP), zone I ROP requiring treatment or zone II ROP
106 that required treatment (posterior pole); (2) control group: infants in control group had
107 no ROP until the age of 40 PMA week. This control group was strictly matched with
108 the ROP group for birth weight (BW) no greater than 200g difference and gestational
109 age (GA) and postmenstrual age (PMA) of no more than 2-week difference.
110 Participants will be excluded from the study if (1) preterm infants who had received
111 any specific ocular treatment for ROP (including photocoagulation, vitrectomy, and
112 intravitreal injections); (2) requested by participants’ families; (3) participants were
113 diagnosed with congenital metabolomic diseases; (4) occurrence of severe
114 complications, including but not limited to, sepsis, necrotizing enterocolitis, neonatal

115 respiratory distress syndrome, and severe metabolic disorder; (5) the mother of the
116 participant had a history of medication and/or serious disease, such as gonorrhoea,
117 syphilis, or AIDS during pregnancy; (6) control group has ROP occurrence in
118 subsequent follow-up visits.

119 **2.2. Diagnosis of ROP**

120 The diagnostic and therapeutic criteria of ROP follow the international
121 classification^[1, 37] and the screening guidelines for retinopathy of prematurity in China
122 (2014)^[17]. All infants were screened using a binocular indirect ophthalmoscope
123 (Heine, Bavaria, Germany) and RetCam (Natus Retcam3, California, United States)
124 until the end of the follow-up. Every infant was examined by two experienced retina
125 specialists independently and the eligibility of participation was confirmed by both
126 the specialists. In our study, the severity of ROP was graded according to
127 the guideline-based on the following criteria.(**Supplementary Table 1**)

128 **2.3. Metabolic profiling**

129 Sample preparation was carried out at Metabolon, Inc. as follows^[14]: recovery
130 standards were added prior to the first step in the extraction process for quality control
131 purposes. To remove protein, dissociate small molecules bound to protein or trapped
132 in the precipitated protein matrix, and to recover chemically diverse metabolites,
133 proteins were precipitated with methanol under vigorous shaking for 2 min (Glen
134 Mills Genogrinder 2000) followed by centrifugation. The resulting extract was
135 divided into five fractions: two for analysis by two separate reverse phases
136 (RP)/UPLC-MS/MS methods with positive ion mode electrospray ionization (ESI),
137 one for analysis by RP/UPLC-MS/MS with negative ion mode ESI, one for analysis
138 by HILIC/UPLC-MS/MS with negative ion mode ESI, and one sample was reserved
139 for backup. Samples were placed briefly on a TurboVap® (Zymark) to remove the
140 organic solvent. The sample extracts were stored overnight under nitrogen before
141 preparation for analysis.

142 Three types of controls were analysed in concert with the experimental samples:

143 1) a pooled matrix sample generated by taking a small volume of each experimental
144 sample served as technical replicate throughout the dataset; 2) extracted water
145 samples served as process blanks; and 3) a cocktail of quality control standards that
146 were carefully chosen not to interfere with the measurement of endogenous
147 compounds were spiked into every analysed sample, allowed instrument performance
148 monitoring and aided chromatographic alignment. Instrument variability was
149 determined by calculating the median relative standard deviation (RSD) for the
150 standards that were added to each sample before injection into the mass spectrometers
151 (median RSD = 6%). Overall process variability was determined by calculating the
152 median RSD for all endogenous metabolites (i.e., non-instrument standards) present
153 in 100% of the pooled human plasma samples (median RSD = 8%). Experimental
154 samples and controls were randomized across the platform run.

155 **2.4. Ultrahigh Performance Liquid Chromatography-Tandem Mass
156 Spectroscopy (UPLC-MS/MS)**

157 The UPLC-MS/MS platform utilized a Waters ACQUITY UPLC and a Thermo
158 Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a
159 heated electrospray ionization (HESI-II) source and Orbitrap mass analyser operated
160 at 35,000 mass resolution. The sample extract was dried then reconstituted in solvents
161 compatible to each of the four methods. Each reconstitution solvent contained a series
162 of standards at fixed concentrations to ensure injection and chromatographic
163 consistency. One aliquot was analysed using acidic positive ion conditions,
164 chromatographically optimized for more hydrophilic compounds. In this method, the
165 extract was gradient eluted from a C18 column (Waters UPLC BEH C18-2.1x100 mm,
166 1.7 µm) using water and methanol, containing 0.05% perfluoropentanoic acid (PFPA)
167 and 0.1% formic acid (FA). Another aliquot was also analysed using acidic positive
168 ion conditions and the extract was gradient eluted from the same aforementioned C18
169 column using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA and was
170 operated at an overall higher organic content. Another aliquot was analysed using

171 basic negative ion optimized conditions using a separate dedicated C18 column. The
172 basic extracts were gradient eluted from the column using methanol and water,
173 however with 6.5mM ammonium bicarbonate at pH 8. The fourth aliquot was
174 analysed via negative ionization following elution from a HILIC column (Waters
175 UPLC BEH Amide 2.1x150 mm, 1.7 μ m) using a gradient consisting of water and
176 acetonitrile with 10mM Ammonium Formate, pH 10.8. The MS analysis alternated
177 between MS and data-dependent MS_n scans using dynamic exclusion. The scan range
178 varied slightly between methods but covered 70-1000 m/z.

179 **2.5. Compound identification, quantification, and data curation**

180 Raw data were extracted, peak-identified and QC processed using Metabolon's
181 hardware and software^[9]. Compounds were identified by comparison to library entries
182 of purified standards or recurrent unknown entities. Metabolon maintains a library
183 based on authenticated standards that contains the retention time/index (RI), mass to
184 charge ratio (m/z), and chromatographic data (including MS/MS spectral data) on all
185 molecules present in the library. Furthermore, biochemical identifications are based
186 on three criteria: retention index within a narrow RI window of the proposed
187 identification, accurate mass match to the library \pm 10 ppm, and the MS/MS forward
188 and reverse scores between the experimental data and authentic standards. The
189 MS/MS scores are based on a comparison of the ions present in the experimental
190 spectrum to the ions present in the library spectrum.

191 Peaks were quantified using area-under-the-curve method. The raw area counts
192 for each metabolite in each sample were normalized to correct for variation resulting
193 from instrument inter-day tuning differences by the median value for each run-day,
194 therefore, setting the medians to 1.0 for each run. This preserved variation between
195 samples but allowed metabolites of widely different raw peak areas to be compared
196 on a similar graphical scale.

197 **2.6. Primary data**

198 Metabolomic data project ID: CALI-020-0001. The non-targeted metabolomics

199 analysis of 831 metabolites in 114 eligible subjects by UPLC-MS/MS method. Each
200 biochemical in OrigScale is rescaled to set the median equal to 1. Then, missing
201 values were imputed with the minimum. Exogenous substances (EDTA, molecular
202 constructs, etc.) was removed. To minimise the effect of extreme numbers on the
203 result, values outside mean \pm 5SD were excluded.^[27].

204 **2.7. Multivariate data analysis and pathway enrichment analysis**

205 Multivariate data analysis was conducted using SIMCA (v.14.1; Umetrics, Umeå,
206 Sweden). Orthogonal partial least squares-discriminant analysis (OPLS-DA) was used
207 to increase the class separation, flatten dataset and locate variable importance in
208 projection (VIP)^[30]. The quality of models was validated using two parameters:
209 R²Ycum (goodness of fit) and cumulated Q² (Q²cum, goodness of prediction). A
210 threshold of 0.5 is widely accepted in model classification to classify good (Q²cum
211 ≥ 0.5) or poor (Q²cum < 0.5) predictive capabilities.

212 We validated the OPLS-DA model using a permutation test (200 times) to reduce
213 the risk of overfitting and possibilities of false-positive findings. Plots show
214 correlation coefficients between the original Y and the permuted Y versus the
215 cumR²Y and Q². Fitted regression lines were also displayed, which connects the
216 observed Q² to the centroid of the permuted Q² cluster. The model was considered
217 valid^[32] if (1) all Q² values from the permuted data set to the left are lower than the
218 Q² value on the actual data set to the right and (2) the regression line has a negative
219 value of intercept on the y-axis. To spot moderate and strong outliers, DModX test
220 and Hoteling's T-squared test were performed. These tests were performed using
221 SIMCA. VIP values were then singled out by supervised investigations. VIP is a
222 readout of the contribution of each variable on the X-axis to the model. It is summed
223 over all components and weighted to the Y accounted for by every single
224 component^[3]. Therefore, VIP ranking reflects the metabolites' contribution to the
225 model. VIP > 0.5 indicate a higher percent variation explained when a metabolite is
226 included in the model; VIP < 0.5 represent metabolite plays a less important role in

227 it^[18]. In this study, we select metabolites with VIP > 0.5 as major discriminant
228 metabolites to expand our selection and pathway enrichment.

229 Pathway analysis and statistical analysis were performed using MetaboAnalyst
230 4.0^[7] with available Human Metabolome Database (HMDB) identifiers. For pathway
231 analysis, metabolites were mapped to the Kyoto Encyclopedia of Genes and Genomes
232 (KEGG)^[28] metabolic pathways, and quantitative pathway enrichment and pathway
233 topology analysis were performed. To select the most discriminant pathways, we
234 chose levels of impact and extremely significant difference (impact>0.3, P<0.05,
235 respectively).

236 Lowess smoothing applied to plot an association between metabolites and the
237 severity of ROP. And the resulting raw values were transformed to z scores using the
238 mean and standard deviation.

239 **2.8. Machine learning**

240 Our simulation experiment was implemented in Python 3.7.7. We first use
241 Chi-Squared (CHI2) to select important features. Random forest (RF) was further
242 performed for classification. RF is a supervised classification technique based on an
243 ensemble of decision trees^[5]. We use the five-fold cross-validation to determine the
244 optimal tuning parameters. The result was the average accuracy of the five-fold
245 cross-validation procedure.

246 **2.9. Statistical analysis**

247 Demographic characteristics were first determined by QQ- and PP-plots.
248 Normally distributed variables were presented as mean ± SD; otherwise, data were
249 presented as median and mean ranks. Two-tailed paired Student's t-Test and paired
250 Wilcoxon tests were then used to compare variables whose distribution followed and
251 did not follow a normal distribution, respectively, between ROP and non-ROP infants.
252 Following log transformation and imputation of missing values, if any, with the
253 minimum observed value for each compound, two-tailed paired Student's t-Test was
254 used to identify biochemicals that differed significantly between groups. Differences

255 were considered significant when $P < 0.05$ as well as those approaching significance
256 ($0.05 < P < 0.10$). The analysis was performed using SPSS, version 25.0. For all
257 conditions, fold changes in metabolite levels relative to control group (non-ROP
258 group) were calculated. Further statistical details can be found in the appropriate
259 figure legends.

260 **Results**

261 **3.1. Demographic Characteristics**

262 The demographic characteristics of the study cohort were presented in **Table 1**.
263 Gestational age, birth weight and PMA of both study groups are strictly matched
264 according to our matching criteria. Statistical differences are identified in delivery
265 mode (cesarean section 33.30% in ROP vs 57.90% in control, $P = 0.008$), feeding
266 strategy on the day (breast milk 43.90% in ROP vs 87.70% in non-ROP, $P < 0.001$)
267 and the amount of leukocyte in the blood ($(8.61 \pm 3.19) \times 10^9/L$ in ROP vs (9.83 ± 3.08)
268 $\times 10^9/L$ in non-ROP, $P = 0.047$) shows statistically significant differences. There is no
269 statistical significance of differences in maternal age ($P = 0.416$), length of stay ($P =$
270 0.146), multiple pregnancy ($P = 0.843$) and sex ($P = 0.570$) between two groups.
271 Interestingly, we did not find a statistically significant difference between two groups
272 with regards to amounts of feeding, oxygen saturations or FiO₂, oxygen inhalation
273 mode on the day of the blood drawn. Previous history of administration of oxygen,
274 switch of oxygen inhalation mode, sepsis and blood transfusion is comparative
275 between ROP and control group. Similarly, no difference was found in concentration
276 of C-reactive and the level of platelet between two groups. Noteworthy, none of them
277 have received insulin infusion.

278

279

280

281 **Table 1. Demographic characteristics of participants.**

Variables	ROP	non-ROP	P Value
Maternal age (years)	30.80 ± 5.19	31.37 ± 3.94	0.556
Hospital length of stay (days)	59	54	0.146
The same NICU (same %)	27 (47.40)	27 (47.40)	1.000
Gestational age (weeks)	28.45 ± 2.43	28.84 ± 2.16	0.416
Birth weight (kilogram)	1.127 ± .324	1.152 ± .291	0.482
Postmenstrual age (weeks)	37.15 ± 2.16	36.45 ± 2.13	0.076
Delivery mode (caesarean section %)	19 (33.30)	33 (57.90)	0.008*
Multiple pregnancy (singleton %)	38 (66.70)	37 (64.90)	0.843
Sex (Male %)	34 (59.60)	31 (54.40)	0.570
Feeding strategy ¹ (breast milk %)	25 (43.90)	50 (87.70)	<0.001*
Amounts of daily feeding ¹ (mL)	300	314	0.524
Oxygen saturations (%)	94	92.5	0.444
FiO ₂ (%)	21	21	0.914
Ventilation mode ² (non-invasive %)	36 (63.20)	32 (56.10)	0.445
Administration of oxygen (days)	45.44 ± 23.05	42.07 ± 21.59	0.232
Switch of inhalation mode (switch%)	50 (87.70)	44 (77.20)	0.140
Sepsis (SPS%)	14 (24.60)	13 (22.80)	0.826
Blood transfusion (%)	49 (86.00)	42 (73.70)	0.102
Leukocyte (x10 ⁹ /L)	8.61 ± 3.19	9.83 ± 3.08	0.047*
C-reactive protein (mg/L)	0.5	0.5	0.324
Platelet (x10 ⁹ /L)	363 ± 139	358 ± 146	0.857


282 In maternal age, administration of oxygen, leukocyte and platelet, data are expressed as
283 mean ± SD, statistical differences are calculated with paired two-tailed Student's t-Test. In
284 hospital length of stay, C-reactive protein, amounts of feeding on the day of the blood draw,
285 oxygen saturations and FiO₂, median values are shown, and statistical differences are
286 calculated by paired Wilcoxon Rank Sum test. Delivery mode, multiple pregnancy status,

287 sex, switch of oxygen inhalation mode, blood transfusion, sepsis, oxygen inhalation mode
288 and feeding strategy in blood draw day were analysed by the Chi-squared test. * $p < 0.05$
289 1. Only feeding strategy on the day of blood drawn was considered.
290 2. Only oxygen inhalation mode used on the day of blood drawn was considered
291
292

293 **3.2. Classification of metabolites**

294 We firstly seek to categorize the total 742 metabolites pulled down from
295 metabolomics analysis. **Figure 1** is a pie chart showing the fraction of eight main
296 classes of metabolites, amongst which, most belongs to lipids (47.04%), followed by
297 amino acids (29.11%). Whereas a relatively smaller fractions of metabolites are
298 related to nucleotides (5.12%), cofactors and vitamins (4.99%), peptides (4.58%) and
299 carbohydrates (4.04%). To compare the changing trend of these metabolite classes
300 between control and ROP group, we constructed a heatmap (**Figure 2**). Most
301 metabolites in lipids, nucleotides and carbohydrates categories are elevated in the
302 ROP group, whereas those in amino acids, energy, cofactors and vitamins are
303 fluctuated. It is worth mentioning that most xenobiotics occupy a small proportion of
304 biochemicals that may indicate less external disturbance. **Supplementary Table 2**
305 provides a summary of quantitative differences between the groups. There are 189
306 metabolites significantly differs, with 89 being elevated in the ROP and 100 lowered
307 in the control. In addition, clear difference was also detected in another 67 metabolites,
308 yet these do not achieve a level of statistical significance.

309




310

311 **Figure 1. Pie chart showing fractions of main metabolite classes.**

312 Categories of metabolites are ordered from the highest to lowest fraction: lipids (47.04%),
313 amino acids (29.11%), nucleotides (5.12%), cofactors and vitamins (4.99%), peptides
314 (4.58%), carbohydrates (4.04%), xenobiotics (3.77%) and energy (1.35%).

315



316

317

Figure 2. Heatmap showing metabolite categories in non-ROP and ROP group

318

319

The colour scales ranging from bright blue (low ratio) to bright red (high ratio) represent the relative ratio of $Y = \text{Log}(Y)$ (intensity) between groups. In general, the level of metabolites in ROP slightly higher than that of non-ROP, especially in lipid.

320


321

322 **3.3. Metabolic pathway enrichment analysis**

323 **3.3.1. OPLS-DA model building and validation**

324 We then investigate the OPLS-DA score plot (**Figure 3**) which revealed a clear
325 and separate clustering between premature infants with and without ROP. Moreover,
326 this OPLS-DA model achieves a R²Ycum of 0.908 and Q²cum of 0.523, meaning an
327 excellent goodness of fit and a reliable predictive capacity.

328 By performing statistical validation of the corresponding OPLS-DA model by
329 permutation testing (200 iterations) (**Supplementary Figure 1A**), we obtained all
330 permuted R²s below or around 0.9 and most permuted Q² below 0. Furthermore, all
331 R² and Q² are lower than the original values on the right. Notably, Q² regression
332 line has a negative intercept at (0, -0.542). These collectively suggest that a valid
333 model fitting which is unlikely to be built by chance. To identify strong and
334 moderate outliers, we performed Hoteling's T-squared test (**Supplementary Figure**
335 **1B**) and DModX test (**Supplementary Figure 1C**), respectively. No strong outliers
336 in the sample can be identified, whereas infant 45 (in the ROP group) seems to show
337 evident deviation in the DModX test.



338

339 **Figure 3. OPLS-DA scatter plot of samples from ROP and non-ROP groups.**

340 Samples from ROP and non-ROP group forms clearly separated clusters in the OPLS-DA
341 analysis. $R^2Y_{cum} = 0.908$, $Q^2_{cum} = 0.523$. Green dots represent ROP ($n = 57$); blue dots
342 represent non-ROP ($n = 57$).

343


344 **3.3.2. Contribution analysis of all metabolites in ROP**

345 Based on the OPLS-DA model, we then construct an contribution plot, which
346 ranks metabolites by their contribution to the model (**Supplementary Figure 2**). For
347 clarity, only the top 78 metabolites are shown. The top three contributors are isocitric
348 lactone, arabinose and mannose. To expand our pathway selection, there are 649
349 metabolites ($VIP > 0.5$) that were considered candidate to pathway enrichment.

350 **3.3.3. Pathway analysis**

351 We use 649 metabolites with VIP values > 0.5 to carry out metabolite set
352 enrichment analysis (MSEA) (**Figure 4**). Pathways at the top right achieve a high
353 impact value and small P value (green box). We primary enriched yielded 9 pathways
354 with obviously statistical significant difference (impact > 0.3 , $P < 0.05$)
355 (**Supplementary Table 3**), including arginine biosynthesis (-Log (P) = 11.584,
356 Impact = 0.538), histidine metabolism (-Log (P) = 9.828, Impact = 0.533), glycine,
357 serine and threonine metabolism (-Log (P) = 7.671, Impact = 0.729), phenylalanine,
358 tyrosine and tryptophan biosynthesis (-Log (P) = 7.099, Impact = 1.000), alanine,
359 aspartate and glutamate metabolism (-Log (P) = 6.832, Impact = 0.741),
360 phenylalanine metabolism (-Log(p) = 5.936, Impact = 0.619), beta-alanine
361 metabolism (-Log (P) = 5.373, Impact = 0.672), taurine and hypotaurine metabolism
362 (-Log (P) = 5.306, Impact = 1.000), arginine and proline metabolism (-Log (P) =
363 3.955, Impact = 0.376).

364




365

366 **Figure 4 Pathway enrichment results.**

367 Pathway impact is determined by topological analysis (x-axis) and enrichment log (P) value
368 is adjusted by the original P value (y-axis). Node colour is based on its P -value, and the
369 node size is based on pathway impact values. The top nine most significantly affected
370 metabolic pathways (Impact > 0.3 , $P < 0.05$) are inside the green box.

371 **3.4. Feature selection and random forest analysis**

372 To narrow down and identify the most optimal biomarker combination that are
373 useful in differentiating ROP from non-ROP infants, we implemented 742 metabolites
374 and then use the chi-square feature selection based random forest method (**Figure 5**).
375 We obtain an unbiased estimate of the predictive performance of the random forest
376 model which typically outputs the top 30 metabolites, the top six are isocitric lactone
377 (variable importance 0.0567); creatinine (0.0416); methylsuccinate (0.0413);
378 arabinose (0.0405); arginine (0.0359) and ribitol (0.0348). However, only differences
379 in creatinine; ribitol; orotidine; cis-4-decenoate (10:1n6); 3-(4-hydroxyphenyl) lactate;
380 undecanoate (11:0); kynurenine and glutamate, gamma-methyl ester achieve statistical
381 significance ($P < 0.05$). Ornithine; 10-undecenoate (11:1n1) and picolinoylglycine
382 have the difference approaches statistical significance ($0.05 < P < 0.10$).
383



384

385 **Figure 5. Random forest graph.**


386 The vertical axis shows the top 30 metabolites and the horizontal axis shows the
387 corresponding importance of the feature. Different colours represent different metabolites
388 classes. Isocitric lactone has the highest feature importance.

389 From the random forest and the pathway enrichment results, we identify 6
390 pathways corresponding to 9 metabolites as the top 30 most significantly affected
391 metabolites in the ROP group (**Figure 6**). In the alanine, aspartate and glutamate
392 metabolism, the average concentration of glutamate, gamma-methyl ester are
393 increased in ROP group compared to controls. This indicates a shift in the redox
394 homeostasis and fatty acid oxidation (FAO), suggesting a more antioxidative state.
395 However, in arginine biosynthesis and arginine and proline metabolism, the average
396 level of ornithine and DMGV is reduced in ROP, whereas arginine is slightly elevated.
397 In addition, in phenylalanine, tyrosine and tryptophan biosynthesis, the
398 indole-3-carboxylate is increases and 3-(4-hydroxyphenyl) lactate and kynurenone
399 shows a decreasing trend in the ROP group.

400 After adjusting for statistically significant differences (delivery mode, feeding
401 strategy and leukocyte), the following metabolites of the first 30 metabolites in
402 random forest remain statistically significant. Creatinine, ribitol and glutamate,
403 gamma-methyl ester that are still independent risk factors for ROP (**Table 2**). The
404 higher the value of creatinine, the lower the risk of ROP, indicating it is a strong
405 protective factor ($P = 0.038$, Wald = 4.308, odds ratio [OR] = 8.1465E-7, confidence
406 interval [CI] = (1.4484E-12, 0.458)). Ribitol is a weak protective factor for ROP (P
407 = 0.016, Wald = 5.770, OR = 0.018, CI = (0.001, 0.476)). The higher the level of
408 glutamate, gamma-methyl ester the higher the risk of ROP, suggesting it being a
409 strong risk factor ($P = 0.015$, Wald = 5.908, OR = 1.6491E+05, CI = (10.238,
410 2.6563E + 09)). Notable metabolites which close to statistical significance ($0.05 < P$
411 < 0.1) show a strong statistically significant after adjusting, namely, ornithine,
412 10-undecenoate (11:1n1) and picolinoylglycine. Therefore, we reasoned that
413 creatinine; ribitol; glutamate, gamma-methyl ester; ornithine; 10-undecenoate
414 (11:1n1) and picolinoylglycine are potential biomarkers of ROP (**Figure 7**). Taken
415 together the results from **Figure 6**, it appears that pathways related to
416 glycometabolism, redox homeostasis, lipid metabolism and arginine, tyrosine and

417 tryptophan metabolic pathway are likely to be closely associated with ROP.

418




419

420 **Figure 6 Correlation heatmap of the top 30 metabolites and pathways selected from**
421 **random forest analysis.**

422 The green wells on the left denote metabolites corresponding to enriched metabolic
423 pathways (on the right with green colour #1, #2, #4, #5, #8 and #9). Statistically significant
424 differences are indicated by a purple triangle on the left and right (adjusted $P < 0.05$).
425 Interestingly, arginine biosynthesis, FAO and redox homeostasis are the results of enriched
426 pathways and both before and after adjustment.

427

428



429

430

Figure 7. Box plot of potential biomarkers of ROP.

431

Creatinine, ribitol and glutamate, gamma-methyl ester shows statistical difference ($P < 0.05$); ornithine, 10-undecenoate (11:1n1) and picolinoylglycine approach statistical significance ($0.05 < P < 0.1$). Light red represents elevated levels of metabolite, and light blue means reduced levels of the metabolites. Circles represent outliers and the plus signs serve as the mean.

435

436

437 **3.5. Biomarkers for ROP**

438 We then investigate the ROC plot to assess how good are the above chosen
439 metabolic biomarkers in predicting ROP (**Supplementary Figure 3**). AUC of
440 potential biomarkers: glutamate, gamma-methyl ester (AUC = 0.642, CI = (0.541,
441 0.743)), ornithine (AUC = 0.671, CI = (0.5719, 0.7694)), creatinine (AUC = 0.572,
442 CI = (0.467, 0.677)), ribitol (AUC = 0.766, CI = (0.6783, 0.8536)), 10-undecenoate
443 (11:1n1) (AUC = 0.602, CI = (0.497, 0.707)), picolinoylglycine (AUC = 0.618, CI =
444 (0.514, 0.722)) are greater than 0.50. Notably, the AUC of ribitol is even greater
445 than 0.766, indicating its reliable predictive ability. According to the hypothesis test
446 ($H_0 = 0.5$), and after adjusting for confounding factors creatinine, ribitol, glutamate,
447 gamma-methyl ester, ornithine, 10-undecenoate (11:1n1) and picolinoylglycine are
448 confirmed to be true positive and do not seem to be obtained randomly (**Table 2**). In
449 particular, the accuracy of ribitol - based diagnosis is the best (AUC = 0.766,
450 sensitivity = 71.9%, and specificity = 71.9%) amongst all potential discriminant
451 metabolites.

Table 2. Adjusted metabolites with statistical differences.

Metabolite	Fold change (ROP/non-ROP)	Adjusted P	OR (95% CI)	FDR
Glutamate, gamma-methyl ester	1.2557	0.015	1.65E+05 (10.24, 2.66E+09)	0.0751
Ornithine	0.9956	0.022	5.99E+04 (5.06, 7.09E+08)	0.2330
Creatinine	0.9319	0.038	8.15E-7 (1.45E-12, 0.46)	0.0198
Ribitol	0.9005	0.016	0.018 (0 .001, 0.48)	0.0198
10-undecenoate (11:1n1)	1.7239	0.028	5.19E+04 (3.18, 8.49E+08)	0.2167
Picolinoylglycine	1.1951	0.011	1.50E+03 (5.21, 4.34E+05)	0.2504
1-carboxyethylisoleucine	1.0836	0.028	0.003 (1.58E-05, 0.535)	0.4163

Methylsuccinate	1.0660	0.013	9.33E+04 (11.474, 7.59E+08)	0.4083
5-hydroxyhexanoate	1.5985	0.020	0.0001 (6.86E-08, 0.248)	0.9163


453 The odds ratio (OR) value, 95% confidence interval (CI) and adjusted *P*-value were calculated by multivariate Logistic regression (considering the delivery
454 mode, feeding strategy and leukocyte count with statistical differences).

455 To investigate correlations between level of potential biomarkers with severity of
456 ROP, we employ the proportional odds model with ordinal logistic regression. The
457 result of parallel lines test suggests a valid proportional odds assumption ($\chi^2 = 12.892$,
458 $P = 1.000$). In goodness-of-fit tests, the deviance test indicated the model fits well (χ^2
459 = 229.829, $P = 1.000$), which is better than the model with only a constant (χ^2
460 = 40.073, $P < 0.001$). we observe that the level of creatinine and ribitol decreases with
461 increased ROP severity ($P = 0.018$, OR = 0.027, 95%CI = (0.001,0.544); $P = 0.011$,
462 OR = 0.448, 95%CI= (0.241,0.834), respectively). However, we do not identify a
463 clear association between glutamate, gamma-methyl ester; ornithine; 10-undecenoate
464 (11:1n1) or picolinoylglycine with ROP severity after adjusting for delivery mode,
465 feeding strategy and leukocyte. Our study provides the very first data indicating a
466 potential association between declined creatinine/ribitol and the severity of ROP.
467 Nonetheless, the Lowess curves of creatinine (first rises and then falls) does not
468 perfectly predict the ROP severity as it did in the proportional odds model , this may
469 be attributed to coarse grading systems, extreme outliers or small number of
470 severe ROP infant (2 infants of AP ROP and 1 infants of stage 4 ROP)
471 (Supplementary Figure 4).

472 Furthermore, we also find that premature with more severe ROP is related to be
473 fed with a combination of breast milk and parenteral nutrition (5.9-fold, 95% CI =
474 (2.564, 13.699), $\chi^2 = 17.315$, $P < 0 .001$), higher spontaneous labour rate (2.3-fold,
475 95%CI = (1.034, 5.115), $\chi^2 = 4.168$, $P = 0 .041$) and higher level of leukocytes
476 (with every 1 ($\times 10^9/L$) increase, the risk of ROP is elevated by 1.1%, 95% CI =
477 (1.001, 1.295), $\chi^2 = 3.928$, $P = 0 .048$). These findings are consistent with our
478 previous study on targeted analysis of blood spot samples from ROP infants^[53]. The
479 reason for a higher fraction of ROP infants born via spontaneous labour may be due
480 to those underwent prolonged labour are more likely to be exposed to lengthened
481 anoxia, which exaggerate fluctuation of oxygen during delivery.
482

483 Beyond this, none of the above 6 potential biomarkers (glutamate,
484 gamma-methyl ester, ornithine, creatinine, ribitol, 10-undecenoate (11:1n1) and
485 picolinoylglycine) were linearly correlated with the change of PMA, BW, and GA by
486 using simple linear regression analysis. (ROP group: R = 0.025, F = 1.43, P =
487 0.237; R = 0.003, F = 0.16, P = 0.689; R = 0.012; F = 0.68, P = 0.413; R =
488 0.019; F = 1.04, P = 0.312; R = 0.041; F = 2.38, P = 0.129; R = 0.011; F = 0.63,
489 P = 0.430, respectively; non-ROP group: R = 0.005; F = 0.29, P = 0.592; R =
490 0.007; F = 0.38, P = 0.539; R = 0.016; F = 0.89, P = 0.350; R = 0.006; F = 0.32,
491 P = 0.576; R < 0.001; F = 0.01, P = 0.920; R = 0.025; F = 1.38, P = 0.245,
492 respectively). We plotted the second order polynomial fits to serve as
493 a correlation between biomarkers and PMA (**Figure 8**). Our study indicating a
494 potential association between glutamate, gamma-methyl ester, ornithine, creatinine,
495 ribitol, 10-undecenoate (11:1n1), picolinoylglycine and risk/severity of ROP, but not
496 the change of PMA, BW and GA.

497



498

499 **Figure 8. Non-linear regression analysis correlation between PMA(days) and**
500 **biomarkers.**

501 The curve was obtained by fitting to a two-parameter model in non-linear regression
502 analysis. Potential biomarkers (glutamate, gamma-methyl ester, ornithine, creatinine,
503 ribitol, 10-undecenoate (11:1n1), and picolinoylglycine) would presumably vary
504 with PMA (days), however, they did not verify the predicted linear relationship. Red
505 lines represent ROP group; black lines represent non-ROP group.

506 | **Discussion**

507 In the present study, we compared the serum metabolomic profiling between
508 strictly matched control and ROP premature infants. Analysis revealed a few altered
509 metabolic pathways and identified 6 major potential biomarkers of ROP, which are
510 reliable at predicting the development and severity of ROP. We will discuss these
511 biomarkers and relevant pathways to illustrate the rationale of them being predictive
512 of ROP. We constructed a comprehensive map of potential pathways identified in the
513 present study to the development of ROP (**Figure 9**).
514

515 **4.1. Glycometabolism and redox homeostasis**

516 ROP is characterized by its vascular abnormality, such as neovascularization.
517 Increased endothelial sprouting and proliferation are major cellular events causing
518 pathological proliferative retinopathies, therefore, deciphering the molecular
519 mechanisms underlying these early cellular events are key to understanding and
520 further developing novel therapeutic approaches for the prevention or treatment of
521 ROP. Our discussion will also focus on the implication of identified metabolite
522 changes in the major vasculature component (i.e., endothelial cells).

523 The retina is one of the most energy-demanding tissues of the body. Under
524 hypoxic conditions, there are still a considerable fraction (80-96%) of glucose being
525 converted to lactate^[24, 25]. Similar to the retina, ECs produce adenosine triphosphate
526 (ATP) by aerobic glycolysis regardless of whether oxygen is present which referred to
527 as the Warburg effect^[11]. Aerobic glycolysis is rapidly increased to supplement
528 cellular energy needs (within seconds to minutes), while oxidative phosphorylation
529 (OXPHOS) is 100 times slower than that of aerobic glycolysis^[44]. These make prompt
530 metabolism to adapt to booming demand on the energy needs, as long as ECs have
531 received stimulation of VEGF. Yizhak et al^[54] also confirmed that ECs migration
532 utilizes aerobic glycolysis to generates ATP rather than OXPHOS.

533 In the current study, we found that the level of glycolytic intermediates, pyruvic
534 acid, pyruvate and lactate, were higher in ROP infants' serum, while the tricarboxylic
535 acid cycle (TCA cycle) metabolites, such as citrate, aconitate and succinylcarnitine
536 (C4-DC), is lower. Such differences are indicative of perturbations in aerobic
537 oxidation. In other words, it demonstrates that aerobic glycolysis is over-active in
538 infants with ROP. In fact, these observations were in accordance with the exuberant
539 proliferation of neovascularization endothelial cells in ROP. In addition, a small
540 amount of mitochondrial pyruvate carrier is responsible for the transport of pyruvate
541 from glycolysis to mitochondria for OXPHOS, which decrease of would also lead to a
542 series of retinal diseases^[20].

543 Increased level of phosphate pentose pathway (PPP) and hexosamine
544 biosynthesis pathway (HBP) provide another line of evidence supporting that the
545 aerobic glycolysis is more active in ROP. Glucose-6-phosphate enters the PPP
546 metabolic pathway under the action of glucose-6-phosphate dehydrogenase (GPD) to
547 promote the synthesis of ribose-5-phosphate, which is necessary for nucleotide
548 biosynthesis^[35]. PPP is composed of oxidized (oxidative branch, oxPPP) and
549 non-oxidized branches (non-oxidative branch, non-oxPPP), the former plays an
550 influential role in the activity and migration of EC^[2, 33]. OxPPP is facilitated by GPD,
551 whose is controlled by VEGF^[13, 34]. In redox homeostasis, ROP group presented
552 elevated levels of cysteine, alpha-ketobutyrate, 2-aminobutyrate, glutathione,
553 glutamate and gamma-methyl ester, which can lead to decreased production of
554 relevant metabolites, such as creatinine. These alternations can also relate to an
555 increase in nicotinamide-adenine dinucleotide phosphate (NADPH) from the oxPPP
556 branch, which maintains redox state of GSH^[34], such state is important in inhibiting
557 the production of reactive oxygen species. It was shown in OIR mice studies that a
558 considerable amount of reactive oxygen species produced by NADPH was clearly
559 associated with retinal neovascularization^[12, 45, 47, 49]. Consistent with increased GSH
560 levels, we found an accumulation of cysteinylglycine in the ROP compared to control,

561 suggesting alteration in gamma-glutamyl transferase (GGT) activity. However, no
562 significant change was identified for gamma-glutamyl amino acids (except for
563 gamma-glutamyltyrosine). In addition, we detected downregulation in several
564 aminosugars, such as N-acetylneuraminate and erythronate. These can be converted
565 from metabolites in the PPP pathway, for instance, ribitol, arabitol/xylitol and
566 sedoheptulose, which were declined in the ROP group. This may also account for that
567 oxPPP and non-oxPPP are interconvertible in the PPP pathway [2] (**Figure 9**).

568 In summary, these results suggest a disruption in glycometabolism and redox
569 imbalance in the serum of ROP infants. This led to an accumulation of correlated
570 metabolites, such as NADPH, GSH and hexosamine, together with a decrease TCA
571 cycle-related molecule. Our prediction model also suggests that, creatinine, ribitol,
572 glutamate and gamma-methyl ester are likely to be potential biomarkers for ROP.

573 **4.2. Lipid metabolism pathway**

574 Compared to control, we found that FAO process in the ROP group is highly
575 active, this is revealed by increased level of most fatty acids, for instance
576 malonylcarnitine (C3DC) which may lead to impaired angiogenesis^[6, 40]. In addition,
577 in the present study we found the level of aspartic acid (nucleotide precursor) and
578 glutamate were also increased in the ROP group. These two amino acids are known to
579 complement each other to produce α -ketoglutarate and maintain protein and/or
580 nucleotide biosynthesis needed for vascular endothelial cell proliferation^[23]. In
581 accordance with the present results, our previous targeted metabolomics study
582 reported a similar change in the C3DC and glutamate in the ROP group^[53].

583 Corresponding to this observation, in omega-oxidation, we also detected
584 elevations in dicarboxylic fatty acids, eicosanedioate (C20-DC) and docosadioate
585 (C22-DC, trending). Although beta-oxidation represents the primary route of fatty
586 acid metabolism, if this process is overwhelmed or impaired,
587 dicarboxylate-generating omega-oxidation (i.e. oxidation of the terminal carbon of
588 fatty acid in peroxisomes and endoplasmic reticulum) may be utilized to help meet

589 energy demand. Several lines of evidence suggest that suppressed carnitine
590 palmitoyltransferase 1A can induce retinal vascular deficiency and reduce
591 pathological angiogenesis in a model of ROP^[40].

592 ECs rely heavily on aerobic glycolysis^[12], whereas FAO provides only
593 contributes to 5% of total ATP production in ECs^[8]. Schoors et al.^[40] proposed that
594 this would ensure ECs have enough *de novo* synthesis of deoxynucleotides during
595 angiogenic sprouting. It also enables ECs to selectively regulate the proliferation,
596 instead of migration, of ECs via FAO. This is consistent to the idea that endothelial
597 migration mainly depends on glycolysis^[54], which suggested that different metabolic
598 pathways regulate different ECs functions in the process of vascular sprouting.
599 Furthermore, Egnatchik et al. demonstrate that systemic FAO blockade with a
600 chemical inhibitor alleviates excessive angiogenesis in a mouse model of retinopathy
601 of prematurity^[38]. With regards to the FAO process, our analysis suggests that
602 10-undecenoate (11:1n1) and picolinoylglycine are potential biomarkers for ROP.

603 **4.3. Arginine metabolism pathway**

604 In this pathway, we found a significantly lower level of ornithine in the ROP
605 group. This is likely to be related to reduced arginase activity and/or the higher
606 ornithine decarboxylase and/or ornithine-oxo-acid transaminase activity. It has been
607 shown that the up-regulation of arginase activity is associated with inflammation,
608 oxidative stress and peripheral vascular dysfunction^[41].


609 These finding is in agreement with the early untargeted metabolomics studies
610 performed in OIR by Lu et al^[15] and plasma metabolites research of ROP infant by
611 Zhou et al^[55]. However, their baseline data are not comprehensive, especially lack the
612 consideration of feeding strategy and administration of oxygen on plasma metabolites,
613 thus the results are not reliable. Besides, results were inconsistent without adjustment
614 confounding factors, and, the method they used is defective (not untargeted, globally
615 accepted standard regimen). What is more, the sample size is too small which will
616 lead to instability. Without mechanism inference, it is neither a network nor a

617 comprehensive view to analyze the possible role of metabolic pathways in the ROP. In
618 the present study, we used a rigorous matching strategy using detailed demographic
619 and clinical information are shown in **Table 1.**, whereas others used self-reported data
620 or less stringent matching. To make our results more reliable and scientific, we use
621 Metabolon, Inc. platform and multiple approaches such as machine learning and
622 multivariate data analysis after adjustment. Therefore, we gave reasonable speculation
623 to several potential pathways for the results.

624 Furthermore, arginase has been recognized as a therapeutic target for CNS
625 disorders and cardiovascular disorders for its role in mediating damage in the retinal
626 neovascularization and targeting early phase of neovessle growth^[36, 39]. In mammalian
627 cells, nitric oxide (NO) is known to regulate angiogenesis, neurotransmissions,
628 immune responses, oxidative stress, and activate endothelial progenitor cells^[16, 39].
629 Arginine is a substrate of NO synthase (NOS) and arginases, these two enzymes
630 counterbalance each other. Therefore, NOS will be activated when arginase activity is
631 inhibited. In addition, during OIR ischemia phase, when arginase activity is
632 downregulated, an increase in iNOS expression, physiologic angiogenesis,
633 vitreoretinal neovascularization and impaired retinal function were reported^[42].
634 Furthermore, Wang et al.^[48] also found that decreased ROS level led to angiogenesis
635 and ECs migration, which is likely to be associated with neovascularization in ROP.

636 On the other hand, increased ornithine decarboxylase activity could lead to
637 excessive production of proline and polyamines, causing collagen deposition,
638 pathological neovascularization and vascular fibrosis^[51]. Moreover, proline is
639 indispensable for the synthesis and maturation of collagen, which is necessary for the
640 maintenance of blood vessel integrity and angiogenesis; additionally, polyamines are
641 vital factors for cell proliferation, ion channel function and neuroprotection^[29].
642 Therefore, upregulated ornithine decarboxylase activity may be a potential contributor
643 for fibrovascular proliferation and retinal detachment at the late stage of ROP.

644



645 **Figure 9. Schematics of potential pathways associated to ROP development.**

646 Red words, increased metabolite in ROP group; Green words, decreased metabolite in ROP
647 group. Red arrows indicate pathways that are more active reaction and green arrows
648 represent a less-active reaction. Purple background denotes key enzymes of relevant
649 pathways.

650 Abbreviations: CPT1 = carnitine palmitoyltransferase 1; PEP = phosphoenolpyruvic acid;
651 ASNS = asparagine synthase; GLS1 = glutaminase 1; GPD = glucose-6-phosphate
652 dehydrogenase; GSH = glutathione; GGT = gamma-glutamyl transferase; SAM =
653 S-adenosylmethionine; SAH = S-adenosylhomocysteine; ASS = argininosuccinate synthase;
654 ASL = argininosuccinate lyase; NOS = nitric oxide synthase; IDO =
655 indoleamine-2,3-dioxygenases.

656

657 **4.4. Limitations of the study**

658 This study is to some extent limited. First, in order to adhere to our strict
659 matching criteria while facing the number of cases diagnosed in south China, the case
660 number is relatively small. While writing this manuscript, we are planning a nationwide
661 and multi-ethnic study, in the hope of acquiring more cases and obtaining a wider
662 scope. Second, to understand the causal roles of metabolic biomarker and disease
663 development and/or progression, one should ideally develop prospective longitudinal
664 studies that allow future disease risks to be evaluated on the basis of multi-omics
665 information or other tissue, such as urine and faeces. This could be a feasible
666 investigation route for the following studies, especially for animal experiments.

667 **Conclusions**

668 This is the first study presenting a multicentre, retrospective case-control study
669 on serum metabolic profiling using non-targeted UPLC-MS/MS to decipher
670 biomarkers for ROP. We propose that creatinine, ribitol, ornithine, 10-undecenoate
671 (11:1n1), picolinoylglycine and glutamate, gamma-methyl ester are potential
672 biomarkers for ROP. Furthermore, creatinine and ribitol are strongly correlated with
673 the severity of ROP. Since these metabolomic changes can be detected between the
674 asymptomatic phase and disease phase, metabolic profiling allows stratification of
675 ROP risk in individuals with latent ROP into high and low-risk individuals,
676 facilitating treatment prior to development of disease pathology when the vessel
677 proliferation is low.

678 Along with identifying high-risk individuals for prophylactic treatment, these
679 risk signatures have potential value for clinical screening of new intervention
680 measures. Selecting such individuals for participation has the potential to increase the
681 power and benefit of clinical screening, and saving medical resources, thereby
682 increasing treatment effectiveness.

683 Undoubtedly, before practical clinical application of a metabolomic signature

684 further studies are necessary. However, blood metabolomic profiles can provide
685 biological information from an ongoing disease individual. We are confident that this
686 study will provide insights into the predictive biomarkers for ROP, and theoretical
687 rationale for the future screening and therapeutic strategies for the ROP.

688 | **Acknowledgments**

689 The authors thank Marcus Fruttiger from Institute of Ophthalmology at University
690 College London for advice and assistance. Also, authors thank the dedication of the
691 Shenzhen ROP Screening Cooperative Group, which includes, but not limited to the
692 neonatal intensive care units of the following hospitals: Shenzhen People's Hospital,
693 Peking University Shenzhen Hospital, Shenzhen Children's Hospital, Shenzhen
694 Maternal and Child Health Hospital, Shenzhen Luohu Maternal and Child Health
695 Hospital, Shenzhen Nanshan Maternal and Child Health Hospital, Baoan Maternity &
696 Child Healthcare Hospital of Shenzhen, Baoan People's Hospital of Shajing Shenzhen,
697 The People's Hospital of Shajing Shenzhen, Huizhou Central People's Hospital,
698 Guangdong Provincial Maternal and Child Health Hospital, Huizhou Sixth People's
699 Hospital, Huizhou Third People's Hospital, Chaonan District Mingsheng Hospital of
700 Shantou, Shantou Second People's Hospital, The Second Affiliated Hospital of
701 Shantou University, Jieyang Huilai People's Hospital, Puning Maternal and Child
702 Health Hospital, Puning People's Hospital, Zhanjiang Central People's Hospital,
703 Affiliated Hospital of Guilin Medical College, Guilin Maternal and Child Health
704 Hospital. All of the study participants are thanked for making this research possible.
705 Special thanks go to Dr.Haibo Peng, Dr.Chaohui Lian and nurse Sisi Luo. Special
706 thanks also go to research assistant Panpan Sun.

707 Supported by Shenzhen Science and Technology Innovation Commission basic
708 discipline layout project, China (JCYJ20170817112542555), and Medical and Health
709 Projects of Sanming.

710 | **Author contributions**

711 Y.Y., J.Z., G.Z., C.L., W.W., and H.H. design the work and acquired multi-center
712 samples. Y.Y., Q.Y. and Y.Z. performed experiments, analyzed data, and wrote the
713 manuscript.

714 **Data availability**

715 All data that support the findings of this study are available within the article
716 and Mendeley dataset. The Supplementary Information, Python code and
717 Metabolomic Data are available in “<https://dx.doi.org/10.17632/7r7xt6pf6x>”, Doi:
718 10.17632/7r7xt6pf6x. Its Demographic Data File are available from the corresponding
719 author upon reasonable request.

720 | References

- 721 [1] An international classification of retinopathy of prematurity. II. The classification of retinal
722 detachment. The International Committee for the Classification of the Late Stages of Retinopathy of
723 Prematurity [J]. Archives of ophthalmology (Chicago, Ill : 1960), 1987, 105(7): 906-12.
- 724 [2] A R-M, WN L, S B, et al. Pentose phosphate cycle oxidative and nonoxidative balance: A
725 new vulnerable target for overcoming drug resistance in cancer [J]. International journal of cancer,
726 2006, 119(12): 2733-41.10.1002/ijc.22227:
- 727 [3] BARNES S, BENTON H P, CASAZZA K, et al. Training in metabolomics research. II.
728 Processing and statistical analysis of metabolomics data, metabolite identification, pathway analysis,
729 applications of metabolomics and its future [J]. Journal of mass spectrometry : JMS, 2016, 51(8):
730 535-48.10.1002/jms.3780:
- 731 [4] BLENCOWE H, LAWN J E, VAZQUEZ T, FIELDER A, GILBERT C. Preterm-associated
732 visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010 [J].
733 Pediatric research, 2013, 74 Suppl 1(35-49.10.1038/pr.2013.205:
- 734 [5] BREIMAN L. Random Forests [J]. Machine Learning, 2001, 45(1):
735 5-32.10.1023/A:1010933404324:
- 736 [6] BRUNING U, MORALES-RODRIGUEZ F, KALUCKA J, et al. Impairment of
737 Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation [J]. Cell metabolism,
738 2018, 28(6): 866-80.e15.10.1016/j.cmet.2018.07.019:
- 739 [7] CHONG J, WISHART D S, XIA J. Using MetaboAnalyst 4.0 for Comprehensive and
740 Integrative Metabolomics Data Analysis [J]. Current protocols in bioinformatics, 2019, 68(1):
741 e86.10.1002/cpbi.86:
- 742 [8] DE BOCK K, GEORGIADOU M, SCHOOERS S, et al. Role of PFKFB3-driven glycolysis in
743 vessel sprouting [J]. Cell, 2013, 154(3): 651-63.10.1016/j.cell.2013.06.037:
- 744 [9] DEHAVEN C D, EVANS A M, DAI H, LAWTON K A. Organization of GC/MS and LC/MS
745 metabolomics data into chemical libraries [J]. Journal of cheminformatics, 2010, 2(1):
746 9.10.1186/1758-2946-2-9:
- 747 [10] DHINGRA D, KATOCH D, DUTTA S, et al. Change in the incidence and severity of
748 Retinopathy of Prematurity (ROP) in a Neonatal Intensive Care Unit in Northern India after 20 years:
749 Comparison of two similar prospective cohort studies [J]. Ophthalmic epidemiology, 2019, 26(3):
750 169-74.10.1080/09286586.2018.1562082:
- 751 [11] DRAOUI N, DE ZEEUW P, CARMELIET P. Angiogenesis revisited from a metabolic
752 perspective: role and therapeutic implications of endothelial cell metabolism [J]. Open biology, 2017,
753 7(12): 170219.10.1098/rsob.170219:
- 754 [12] E G, C S, PA G, et al. NADH Shuttling Couples Cytosolic Reductive Carboxylation of
755 Glutamine with Glycolysis in Cells with Mitochondrial Dysfunction [J]. Molecular cell, 2018, 69(4):
756 581-93.e7.10.1016/j.molcel.2018.01.034:
- 757 [13] EELEN G, DE ZEEUW P, TREPS L, et al. Endothelial Cell Metabolism [J]. Physiological
758 reviews, 2018, 98(1): 3-58.10.1152/physrev.00001.2017:
- 759 [14] EVANS A, BRIDGEWATER B, LIU Q, et al. High resolution mass spectrometry improves
760 data quantity and quality as compared to unit mass resolution mass spectrometry in high-throughput


- 761 profiling metabolomics [J]. Metabolomics, 2014, 4(2): 1.
- 762 [15] F L, Y L, Y G, et al. Metabolomic changes of blood plasma associated with two phases of rat
763 OIR [J]. Experimental eye research, 2020, 190(107855.10.1016/j.exer.2019.107855:
- 764 [16] FORSTERMANN U, SESSA W C. Nitric oxide synthases: regulation and function [J]. Eur
765 Heart J, 2012, 33(7): 829-37.
- 766 [17] FUNDUS GROUP C S O O. Chinese guideline for screening retinopathy of
767 prematurity(2014) [J]. Chinese Journal of Ophthalmology, 2014, 50(12): 933-5.
- 768 [18] GALINDO-PRIETO B. Novel variable influence on projection (VIP) methods in OPLS,
769 O2PLS, and OnPLS models for single-and multi-block variable selection: VIPOPLS, VIPO2PLS, and
770 MB-VIOP methods [D]; Umeå University, 2017.
- 771 [19] GILBERT C, RAHI J, ECKSTEIN M, O'SULLIVAN J, FOSTER A. Retinopathy of
772 prematurity in middle-income countries [J]. Lancet (London, England), 1997, 350(9070):
773 12-4.10.1016/s0140-6736(97)01107-0:
- 774 [20] GRENNELL A, WANG Y, YAM M, et al. Loss of MPC1 reprograms retinal metabolism to
775 impair visual function [J]. Proceedings of the National Academy of Sciences of the United States of
776 America, 2019, 116(9): 3530-5.10.1073/pnas.1812941116:
- 777 [21] HELLSTROM A, SMITH L E, DAMMANN O. Retinopathy of prematurity [J]. Lancet
778 (London, England), 2013, 382(9902): 1445-57.10.1016/s0140-6736(13)60178-6:
- 779 [22] HOPPE G, YOON S, GOPALAN B, et al. Comparative systems pharmacology of HIF
780 stabilization in the prevention of retinopathy of prematurity [J]. Proceedings of the National Academy
781 of Sciences of the United States of America, 2016, 113(18): E2516-25.10.1073/pnas.1523005113:
- 782 [23] HUANG H, VANDEKEERE S, KALUCKA J, et al. Role of glutamine and interlinked
783 asparagine metabolism in vessel formation [J]. The EMBO journal, 2017, 36(16):
784 2334-52.10.15252/embj.201695518:
- 785 [24] J D, A Y, K K, et al. Reductive carboxylation is a major metabolic pathway in the retinal
786 pigment epithelium [J]. Proceedings of the National Academy of Sciences of the United States of
787 America, 2016, 113(51): 14710-5.10.1073/pnas.1604572113:
- 788 [25] J D, W C, L C, et al. Cytosolic reducing power preserves glutamate in retina [J]. Proceedings
789 of the National Academy of Sciences of the United States of America, 2013, 110(46):
790 18501-6.10.1073/pnas.1311193110:
- 791 [26] JM B, JP C, A B, et al. Automated Diagnosis of Plus Disease in Retinopathy of Prematurity
792 Using Deep Convolutional Neural Networks [J]. JAMA ophthalmology, 2018, 136(7):
793 803-10.1001/jamaophthalmol.2018.1934:
- 794 [27] K I, Y O, JH B, et al. A global multicenter study on reference values: 1. Assessment of
795 methods for derivation and comparison of reference intervals [J]. Clinica chimica acta; international
796 journal of clinical chemistry, 2017, 467(70-82.10.1016/j.cca.2016.09.016:
- 797 [28] KANEHISA M, FURUMICHI M, TANABE M, SATO Y, MORISHIMA K. KEGG: new
798 perspectives on genomes, pathways, diseases and drugs [J]. Nucleic acids research, 2017, 45(D1):
799 D353-d61.10.1093/nar/gkw1092:
- 800 [29] LENIS Y Y, ELMETWALLY M A, MALDONADO-ESTRADA J G, BAZER F W.
801 Physiological importance of polyamines [J]. Zygote (Cambridge, England), 2017, 25(3):
802 244-55.10.1017/s0967199417000120:

- 803 [30] LI F, GONZALEZ F J, MA X. LC-MS-based metabolomics in profiling of drug metabolism
804 and bioactivation [J]. *Acta Pharmaceutica Sinica B*, 2012, 2(2): 118-25.
- 805 [31] LIEGL R, HELLSTROM A, SMITH L E. Retinopathy of prematurity: the need for
806 prevention [J]. *Eye and brain*, 2016, 8(91-102.10.2147/eb.s99038):
- 807 [32] MAHADEVAN S, SHAH S L, MARRIE T J, SLUPSKY C M. Analysis of metabolomic
808 data using support vector machines [J]. *Analytical chemistry*, 2008, 80(19):
809 7562-70.10.1021/ac800954c:
- 810 [33] P V, S S-T, G A-V, et al. Characterization of the metabolic changes underlying growth factor
811 angiogenic activation: identification of new potential therapeutic targets [J]. *Carcinogenesis*, 2009,
812 30(6): 946-52.10.1093/carcin/bgp083:
- 813 [34] PAN S, WORLD C J, KOVACS C J, BERK B C. Glucose 6-phosphate dehydrogenase is
814 regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells [J]. *Arteriosclerosis,
815 thrombosis, and vascular biology*, 2009, 29(6): 895-901.10.1161/ATVBAHA.109.184812:
- 816 [35] PANDOLFI P P, SONATI F, RIVI R, et al. Targeted disruption of the housekeeping gene
817 encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but
818 essential for defense against oxidative stress [J]. *The EMBO journal*, 1995, 14(21): 5209-15.
819 <https://pubmed.ncbi.nlm.nih.gov/7489710>
- 820 [36] PERNOW J, JUNG C. The Emerging Role of Arginase in Endothelial Dysfunction in
821 Diabetes [J]. *Current vascular pharmacology*, 2016, 14(2):
822 155-62.10.2174/1570161114666151202205617:
- 823 [37] PREMATURITY I C F T C O R O. The International Classification of Retinopathy of
824 Prematurity revisited [J]. *Archives of ophthalmology (Chicago, Ill : 1960)*, 2005, 123(7):
825 991-9.10.1001/archopht.123.7.991:
- 826 [38] RA E, RJ D. Metabolism: Growth in the fat lane [J]. *Nature*, 2015, 520(7546):
827 165-6.10.1038/nature14375:
- 828 [39] RW C, PC R, HA T, SP N, RB C. Arginase: A Multifaceted Enzyme Important in Health and
829 Disease [J]. *Physiological reviews*, 2018, 98(2): 641-65.10.1152/physrev.00037.2016:
- 830 [40] SCHOOERS S, BRUNING U, MISSIAEN R, et al. Fatty acid carbon is essential for dNTP
831 synthesis in endothelial cells [J]. *Nature*, 2015, 520(7546): 192-7.10.1038/nature14362:
- 832 [41] SHOSHA E, FOUDA A Y, NARAYANAN S P, CALDWELL R W, CALDWELL R B. Is the
833 Arginase Pathway a Novel Therapeutic Avenue for Diabetic Retinopathy? [J]. *Journal of clinical
834 medicine*, 2020, 9(2): 10.3390/jcm9020425:
- 835 [42] SP N, JS S, AS, et al. Arginase 2 deletion reduces neuro-glial injury and improves retinal
836 function in a model of retinopathy of prematurity [J]. *PloS one*, 2011, 6(7):
837 e22460.10.1371/journal.pone.0022460:
- 838 [43] STERNBERG P, JR., DURRANI A K. Evolving Concepts in the Management of
839 Retinopathy of Prematurity [J]. *American journal of ophthalmology*, 2018,
840 186(xxiii-xxxii.10.1016/j.ajo.2017.10.027:
- 841 [44] TP, SS, SB. Cooperation and competition in the evolution of ATP-producing pathways [J].
842 *Science (New York, NY)*, 2001, 292(5516): 504-7.10.1126/science.1058079:
- 843 [45] USHIO-FUKAI M, NAKAMURA Y. Reactive oxygen species and angiogenesis: NADPH
844 oxidase as target for cancer therapy [J]. *Cancer Lett*, 2008, 266(1): 37-52.10.1016/j.canlet.2008.02.044:

- 845 [46] WANG D, DUKE R, CHAN R P, CAMPBELL J P. Retinopathy of prematurity in Africa: a
846 systematic review [J]. Ophthalmic epidemiology, 2019,
847 10.1080/09286586.2019.1585885:1-8.10.1080/09286586.2019.1585885:
- 848 [47] WANG H, YANG Z, JIANG Y, HARTNETT M E. Endothelial NADPH oxidase 4 mediates
849 vascular endothelial growth factor receptor 2-induced intravitreal neovascularization in a rat model of
850 retinopathy of prematurity [J]. Molecular vision, 2014, 20(231-41).
- 851 [48] WANG Y, ZANG Q S, LIU Z, et al. Regulation of VEGF-induced endothelial cell migration
852 by mitochondrial reactive oxygen species [J]. American journal of physiology Cell physiology, 2011,
853 301(3): C695-704.10.1152/ajpcell.00322.2010:
- 854 [49] WILKINSON-BERKA J L, RANA I, ARMANI R, AGROTIS A. Reactive oxygen species,
855 Nox and angiotensin II in angiogenesis: implications for retinopathy [J]. Clinical science (London,
856 England : 1979), 2013, 124(10): 597-615.10.1042/CS20120212:
- 857 [50] WISHART D S. Emerging applications of metabolomics in drug discovery and precision
858 medicine [J]. Nature reviews Drug discovery, 2016, 15(7): 473-84.10.1038/nrd.2016.32:
- 859 [51] Y D, K N, M M, et al. Localization of Acrolein-Lysine Adduct in Fibrovascular Tissues of
860 Proliferative Diabetic Retinopathy [J]. Current eye research, 2017, 42(1):
861 111-7.10.3109/02713683.2016.1150491:
- 862 [52] YANG C S, WANG A G, SUNG C S, et al. Long-term visual outcomes of laser-treated
863 threshold retinopathy of prematurity: a study of refractive status at 7 years [J]. Eye (London, England),
864 2010, 24(1): 14-20.10.1038/eye.2009.63:
- 865 [53] YANG Y, WU Z, LI S, et al. Targeted Blood Metabolomic Study on Retinopathy of
866 Prematurity [J]. Investigative ophthalmology & visual science, 2020, 61(2): 12-.10.1167/iovs.61.2.12:
- 867 [54] YIZHAK K, SE L D, VM R, et al. A computational study of the Warburg effect identifies
868 metabolic targets inhibiting cancer migration [J]. Molecular systems biology, 2014,
869 10(744).10.15252/msb.20134993:
- 870 [55] ZHOU Y, XU Y, ZHANG X, et al. Plasma metabolites in treatment-requiring retinopathy of
871 prematurity: Potential biomarkers identified by metabolomics [J]. Experimental eye research, 2020,
872 199(108198).10.1016/j.exer.2020.108198:
- 873
- 874

875


Supplementary Information



876

877 **Supplementary Figure 1. Validity tests for the OPLS-DA model.**

878 (A) Permutation analysis plotting R₂ and Q₂ from 200 permutation tests in the OPLS-DA
879 model. The y-axis shows R₂ and Q₂, whereas the x-axis shows the correlation coefficient of
880 permuted and observed data. The two points on the right represent the observed R₂ and Q₂.
881 Cluster of points on the left represents 200 permuted R₂ and Q₂. Green and blue dots
882 represent R₂ and Q₂ values, respectively. Dashed lines denote corresponding fitted
883 regression lines for observed and permuted R₂ and Q₂. (B) Hoteling's T-squared test
884 revealed that most samples did not show deviation, except participants 40 ($T^2 = 12.43$), 48
885 ($T^2 = 12.90$) 53 ($T^2 = 14.26$) and 96 ($T^2 = 15.23$) that exceeded 95% confidence interval
886 [CI] level but lower 99% CI level, three of these deviators were from the ROP group and
887 one from the non-ROP group. Red and orange horizontal dashed line denotes 99% and 95%
888 CI level, respectively. (C) DModX test plot presented that most samples did not show
889 severe deviation in DModX, five moderate outliers being participant 43 (1.31), 45 (1.44),
890 55 (1.21), 82 (1.29), 87 (1.35), respectively. Red horizontal dashed line denotes 95% CI.
891
892
893
894
895
896
897
898
899
900
901
902
903
904




905

906

907 **Supplementary Figure 2. Metabolites' contribution plot based on OPLS-DA**
908 **model.**

909 Contribution plot shows the contribution of each metabolites in the previously built
910 OPLS-DA model. According to the plot, there are 649 metabolites perceived as important
911 with VIP value greater than 0.5 (not shown all). Only 78 metabolites were shown in the
912 graph.
913

914



915

916

917 **Supplementary Figure 3. ROC of potential discriminant metabolites for**
918 **ROP.**

919 Ribitol is the best among all potential discriminant metabolites at predicting ROP with high
920 sensitivity (71.9%) and specificity (71.9%); followed by ornithine (sensitivity = 66.7% and
921 specificity = 64.9%), which is notably inferior at predicting than ribitol.

922

923

924

925

926

927

928

929

930


931

932

933

934

935



936 **Supplementary Figure 4. Associations of potential metabolic biomarkers with ROP**
937 **severity.**

938 The associations of potential metabolic biomarkers with ROP severity are plotted with
939 Lowess curves which colors indicate chemical classes: Amino acids = brown; carbohydrates
940 = grey; lipids = light blue. Y-axis denotes standardized values (z-score), while the x-axis is
941 the ROP severity. As the figure shows, the level of glutamate, gamma-methyl ester
942 increased with the severity of the disease; ornithine and creatinine elevate with variation.
943 However, ribitol, 10-undecenoate (11:1n1) and picolinoylglycine decreased with severity.

944

945

946

947

948

949

950 **Tables**

951 **Supplementary Table 1. ROP severity category.**

Grade	Patients condition	Number
0	Non-ROP	57
1	Stage 2 ~ 3 in Zone II without +	8
2	Zone II Stage 3 + ~ ++/ pre - threshhold disease	39
3	Zone II Stage 3 +++/ threshhold disease	7
4	AP ROP	2
5	Stage 4	1

952 Aggressive posterior ROP (AP ROP); “+” denotes plus disease.

953

954

955

956

957

958

959

960

961

962

963

964

965

966

967

968

969

970

971

972 **Supplementary Table 2. Summary of inter-group metabolomic differences.**

Statistical comparisons	
Paired student's t-tests	ROP Control
Total biochemicals ($p < 0.05$)	189
biochemicals (↑ ↓)	89 100
Total biochemicals ($0.05 < p < 0.1$)	67
biochemicals (↑ ↓)	58 9

973 The table shows statistically significant biochemicals profiled in this study. Red and green
974 colour indicate $P \leq 0.05$ (red indicates a significantly higher value, while green denotes
975 significantly lower value). Light red and light green shaded arrows indicate $0.05 < P < 0.10$
976 (Light red shaded indicates a higher value, while light green shaded denotes lower value,
977 but such difference is not statistically significant).

978

979

980

981

982

983

984

985

986

987

988

989

990

991

992

993 **Supplementary Table 3. Enriched pathways.**

994 The top nine pathways are shown with -Log(P), impact and false discovery rate

Rank	Pathway	Log(P)	Impact	FDR
1	Arginine biosynthesis	11.584	0.538	0.001
2	Histidine metabolism	9.828	0.533	0.002
3	Glycine, serine and threonine metabolism	7.671	0.729	0.008
4	Phenylalanine, tyrosine and tryptophan biosynthesis	7.099	1.000	0.012
5	Alanine, aspartate and glutamate metabolism	6.832	0.741	0.013
6	Phenylalanine metabolism	5.936	0.619	0.028
7	beta-Alanine metabolism	5.373	0.672	0.042
8	Taurine and hypotaurine metabolism	5.306	1.000	0.042
9	Arginine and proline metabolism	3.955	0.376	0.134

995 (FDR). A low FDR ($q < 0.10$) is an indication of high confidence in a result. While a higher
996 q -value indicates diminished confidence, it does not necessarily rule out the significance of
997 a result.

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009